The field of cell and gene therapies will provide structural growth opportunities for the next decade. Yet, there are many technical limitations in terms of development or manufacturability, in particular during the ex vivo cell engineering step, the process Mekonos’ platform is revolutionizing. Mekonos is advancing a proprietary ex vivo cell engineering platform – featuring microfluidics, microelectromechanical systems (MEMS) and surface chemistry – for hyper-precise delivery of molecules into many types of cells while maintaining high cell viability, even with fragile cells. Mekonos’ platform is a true enabling technology to facilitate the development of the next generation of cell therapies.

The company is headquartered in San Francisco, California.